Cravath, Goodwin Pilot Viatris' Up To $3.34B Biosimilars Deal
Cravath-led Viatris Inc. plans to sell its biosimilars portfolio to Indian pharmaceutical business Biocon Biologics Ltd., guided by Goodwin, for up to $3.34 billion, the global health care company said Monday....To view the full article, register now.
Already a subscriber? Click here to view full article